Stock 603676 TIBET WEIXINKANG MEDICINE CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tibet Weixinkang Medicine Co., Ltd.

Equities

603676

CNE100002QQ3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 09/05/2024 BST 		5-day change 1st Jan Change
9.59 CNY -0.93% Intraday chart for Tibet Weixinkang Medicine Co., Ltd. +4.92% -8.05%
05-06 Tibet Weixinkang Medicine's Unit Gets Nod for Potassium Aspartate Injection's Production MT
04-25 Tibet Weixinkang Medicine Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 4,767 4,488 3,803 4,051 6,928 4,539
Enterprise Value (EV) 1 4,311 3,958 3,227 3,344 6,127 3,652
P/E ratio 66.3 x 81.6 x 64.2 x 40.4 x 38.8 x 20.9 x
Yield 0.49% 0.42% 1.06% 1.72% 1.48% -
Capitalization / Revenue 6.39 x 6.06 x 5.31 x 3.92 x 4.95 x 3.43 x
EV / Revenue 5.78 x 5.34 x 4.51 x 3.24 x 4.38 x 2.76 x
EV / EBITDA 65.4 x 61.6 x 47.4 x 27 x 32.3 x 19.4 x
EV / FCF -116 x 10.1 x 59 x 25.7 x 116 x 46 x
FCF Yield -0.86% 9.87% 1.69% 3.89% 0.86% 2.17%
Price to Book 5.31 x 4.83 x 3.87 x 3.79 x 5.68 x 3.31 x
Nbr of stocks (in thousands) 423,000 423,000 423,000 436,029 435,162 435,162
Reference price 2 11.27 10.61 8.990 9.290 15.92 10.43
Announcement Date 25/04/19 27/04/20 28/04/21 28/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 746.3 741 715.7 1,034 1,399 1,323
EBITDA 1 65.94 64.31 68.03 123.9 189.9 188.2
EBIT 1 43.53 38.02 37.43 92.92 154.5 145.4
Operating Margin 5.83% 5.13% 5.23% 8.99% 11.05% 11%
Earnings before Tax (EBT) 1 77.74 65.93 69.62 114.2 182.4 215.8
Net income 1 73.44 55.68 58.42 95.91 177 214
Net margin 9.84% 7.51% 8.16% 9.28% 12.65% 16.18%
EPS 2 0.1700 0.1300 0.1400 0.2300 0.4100 0.5000
Free Cash Flow 1 -37.25 390.7 54.65 130.2 52.74 79.37
FCF margin -4.99% 52.73% 7.64% 12.59% 3.77% 6%
FCF Conversion (EBITDA) - 607.54% 80.34% 105.1% 27.78% 42.17%
FCF Conversion (Net income) - 701.75% 93.55% 135.73% 29.81% 37.08%
Dividend per Share 2 0.0550 0.0450 0.0950 0.1600 0.2350 -
Announcement Date 25/04/19 27/04/20 28/04/21 28/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 457 530 576 707 801 887
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -37.2 391 54.7 130 52.7 79.4
ROE (net income / shareholders' equity) 8.37% 6.09% 6.11% 9.36% 15.5% 16.7%
ROA (Net income/ Total Assets) 2.42% 1.87% 1.76% 4.07% 6.11% 5.28%
Assets 1 3,039 2,976 3,327 2,358 2,895 4,052
Book Value Per Share 2 2.120 2.200 2.320 2.450 2.800 3.150
Cash Flow per Share 2 0.3600 0.3800 0.5200 0.5600 1.190 0.6300
Capex 1 94.5 43.7 54.3 55.6 77.7 70.8
Capex / Sales 12.66% 5.89% 7.59% 5.38% 5.56% 5.35%
Announcement Date 25/04/19 27/04/20 28/04/21 28/04/22 25/04/23 25/04/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
TIBET WEIXINKANG MEDICINE CO., LTD. Stock Tibet Weixinkang Medicine Co., Ltd.
-8.05% 578M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.88% 43.27B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+25.54% 22.92B
SANDOZ GROUP AG Stock Sandoz Group AG
+20.29% 15.43B
CIPLA LIMITED Stock Cipla Limited
+13.70% 12.95B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+42.80% 11.83B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.13% 6.91B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+13.13% 5.55B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603676 Stock
  4. Financials Tibet Weixinkang Medicine Co., Ltd.